Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Maxer who wrote (263)	7/10/1998 11:43:00 AM
From: Anthony Wong	Respond to of 642

Zeneca's Tamoxifen Cancer Studies Contradict U.S. Trial Results Bloomberg News July 9, 1998, 10:44 p.m. PT London, July 10 (Bloomberg) -- Zeneca Group Plc's tamoxifen drug has been shown to have no effect in preventing breast cancer in women with a family history of the disease, according to two studies published in today's edition of the Lancet magazine, The Daily Telegraph reported. The studies contradict a 30 million pound ($49 million) U.S. trial of the drug whose authors said in April they had found ''a dramatic advantage'' for women using tamoxifen, and that the anti-oestrogen drug could halve the risk of breast cancer, the paper said. A British study begun in 1986 and led by Trevor Powles of the Royal Marsden Hospital reports that of 2,500 women with a family history of breast cancer, the drug and placebo groups were equally likely to develop the disease; a second Italian study of 5,500 women with hysterectomies also found no difference, the paper reported. Treatments developed by Genentech Inc., Eli Lilly & Co., Bristol-Myers Squibb Co. and others offer hope in the battle to fight and prevent breast cancer, according to studies released May 18 at a medical meeting in Los Angeles. (Daily Telegraph 7/10 p. 6 www.telegraph.co.uk) --Iain Rogers in the London newsroom (44 171) 330 7699 gc